Vitals Knowledge Vault

Factor XIa

3 min read

Factor XIa

What it is

Factor XI (FXI) is a zymogen circulating in plasma. Upon activation to FXIa — by Factor XIIa, thrombin, or autocatalysis — it activates Factor IX, amplifying thrombin generation through the intrinsic tenase complex (FVIIIa + FIXa). This creates an amplification loop relatively independent of tissue factor–driven (extrinsic) coagulation.

The intrinsic pathway is disproportionately important in arterial thrombosis — platelet-rich “white clot” formed on atherosclerotic plaque rupture or erosion. It plays a minimal role in primary hemostasis or in fibrin-rich “red clot” generated in atrial fibrillation.

Why it matters

Humans with congenital FXI deficiency have markedly reduced ischemic stroke risk with only mild bleeding diathesis (primarily post-surgical/traumatic, not spontaneous). This separable protection-from-bleeding profile — reduced thrombosis without severe bleeding — is the biological foundation for FXIa as a therapeutic target.

This natural experiment is the key evidence layer supporting pharmacological FXIa inhibition.

The intrinsic amplification loop

FXIIa → FXIa → FIXa → (with FVIIIa) → FXa → FIIa (thrombin)
                ↑                            ↑
            autocatalysis            thrombin also activates FXI

Contrast with the extrinsic (tissue factor) pathway:

Tissue Factor → FVIIa → FIXa + FXa → FIIa (thrombin)

Drug class comparison

Drug ClassTargetRole of FXIa
Heparin / LMWHFactor IIa + Xa (via antithrombin)Indirect, broad
WarfarinVitamin K–dependent factors (II, VII, IX, X)Indirect, liver synthesis
DabigatranFactor IIa (direct)No FXIa role
Rivaroxaban / Apixaban / EdoxabanFactor Xa (direct)No FXIa role
FXIa inhibitors (asundexian, milvexian)Factor XIa (direct)Blocks intrinsic amplification

Clinical evidence for the mechanism

  • FXI-deficient humans: reduced ischemic stroke, mild bleeding (primarily procedural)
  • Asundexian (OCEANIC-STROKE, Phase 3): 26% RRR in recurrent non-cardioembolic ischemic stroke, no excess major bleeding
  • Milvexian (LIBREXIA-Stroke, Phase 3 ongoing): BID dosing; competing FXIa inhibitor

Class limitation: atrial fibrillation

FXIa inhibition failed in atrial fibrillation — osocimedanab (BMS-986177, Milestone-AF, NCT04272814) terminated early for lack of efficacy. This is mechanistically coherent: AF generates fibrin-rich clot via the extrinsic pathway where FXIa plays a minimal role. The class is not uniformly antithrombotic.

This does not invalidate FXIa inhibition for non-cardioembolic arterial thrombosis.

Vitals relevance

No current wearable biomarker can proxy FXIa activity, coagulation status, or FXIa inhibitor efficacy. HRV, HR, sleep, and activity are not validated surrogates.

FXIa inhibition matters for Vitals in the secondary stroke prevention coaching context — optimizing BP, LDL-C, HbA1c, smoking cessation, and physical activity as foundational stack elements that complement but do not replace FXIa inhibitor therapy.

  • Asundexian — first-in-class oral FXIa inhibitor; positive Phase 3 in non-cardioembolic stroke
  • Milvexian — competing FXIa inhibitor; Phase 3 ongoing (LIBREXIA-Stroke)
  • Cardiovascular risk — broader cardiovascular risk management framework

Graph View

Backlinks